Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Serpin inhibitors for the treatment of prion and prion like diseases

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIT20210421001
Publicado:
28/04/2021
Caducidad:
29/04/2022
Resumen:
A research group based in Italy has developed a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce prion protein (PrPSc) accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. They are looking for licence agreements and joint venture agreements with pharma companies and/or financial agreements with investors.

Details

Tittle:
Serpin inhibitors for the treatment of prion and prion like diseases
Summary:
A research group based in Italy has developed a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce prion protein (PrPSc) accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. They are looking for licence agreements and joint venture agreements with pharma companies and/or financial agreements with investors.
Description:
To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of anti-psychotics, such as quetiapine and clonazepam, to treat myoclonus and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression.
Indeed, through this invention, the technology transfer office of a research center based in the North of Italy and internationally renowned, is presenting a new class of small molecules. These small molecules are acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases.
The development of specific inhibitors of SERPINA3 with an activity in the nano-molar range is expected. The characterization of structural models of the binding of the small molecules with the protein should allow the identification of novel inhibitors with improved potency.
The research center is looking for licence agreements or joint ventures with industry (pharma companies) or financial agreements with investors interested in developing new drugs.
Advantages and Innovations:
Advantages and Innovations So far there are no effective therapies for prion diseases. The proposed technology aims at developing novel molecules with improved efficacy on these diseases.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The patent owners are: Italian Research Center 1 (50%), German Research Center (37.5%) and Italian Research Center 2 (12.5%). The European search report has shown a complete novelty and inventive step. Supplementary material and supporting data available upon request.

Partner sought

Type and Role of Partner Sought:
Pharma companies/Investors interested in acquiring and co-developing the technology in the frame of financial, joint venture and license agreement.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Italian

Keywords

Technology Keywords:
06001014 Neurología, investigación cerebral